These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 29040287)
21. Target site antimicrobial activity of colistin might be misestimated if tested in conventional growth media. Matzneller P; Strommer S; Österreicher Z; Mitteregger D; Zeitlinger M Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1989-94. PubMed ID: 26178070 [TBL] [Abstract][Full Text] [Related]
22. In vitro synergistic antimicrobial effect of imipenem and colistin against an isolate of multidrug-resistant Enterobacter cloacae. Lin KH; Chuang YC; Lee SH; Yu WL J Microbiol Immunol Infect; 2010 Aug; 43(4):317-22. PubMed ID: 20688292 [TBL] [Abstract][Full Text] [Related]
23. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. Personne Y; Curtis MA; Wareham DW; Waite RD J Antimicrob Chemother; 2014 Dec; 69(12):3236-43. PubMed ID: 25134721 [TBL] [Abstract][Full Text] [Related]
24. Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Chosidow S; Fantin B; Nicolas I; Mascary JB; Chau F; Bordeau V; Verdier MC; Rocheteau P; Guérin F; Cattoir V; de Lastours V Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671282 [TBL] [Abstract][Full Text] [Related]
25. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Hornsey M; Phee L; Longshaw C; Wareham DW Int J Antimicrob Agents; 2013 Mar; 41(3):285-7. PubMed ID: 23312607 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523 [TBL] [Abstract][Full Text] [Related]
28. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii. Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259 [TBL] [Abstract][Full Text] [Related]
29. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. Yau W; Owen RJ; Poudyal A; Bell JM; Turnidge JD; Yu HH; Nation RL; Li J J Infect; 2009 Feb; 58(2):138-44. PubMed ID: 19058855 [TBL] [Abstract][Full Text] [Related]
31. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960 [TBL] [Abstract][Full Text] [Related]
32. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. Berçot B; Poirel L; Dortet L; Nordmann P J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739 [TBL] [Abstract][Full Text] [Related]
33. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Albur MS; Noel A; Bowker K; MacGowan A Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065 [TBL] [Abstract][Full Text] [Related]
34. Molecular epidemiology of colistin-resistant Enterobacteriaceae in inpatient and avian isolates from China: high prevalence of mcr-negative Klebsiella pneumoniae. Wang X; Liu Y; Qi X; Wang R; Jin L; Zhao M; Zhang Y; Wang Q; Chen H; Wang H Int J Antimicrob Agents; 2017 Oct; 50(4):536-541. PubMed ID: 28668693 [TBL] [Abstract][Full Text] [Related]
35. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii. Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048 [TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa. Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Hornsey M; Phee L; Stubbings W; Wareham DW Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926 [TBL] [Abstract][Full Text] [Related]
38. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Marie MA; Krishnappa LG; Alzahrani AJ; Mubaraki MA; Alyousef AA Bosn J Basic Med Sci; 2015 Oct; 15(4):24-9. PubMed ID: 26614848 [TBL] [Abstract][Full Text] [Related]
39. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol. Wei WJ; Yang HF Int J Antimicrob Agents; 2017 Mar; 49(3):321-326. PubMed ID: 28167347 [TBL] [Abstract][Full Text] [Related]
40. Introducing [Mn(CO)3(tpa-κ(3)N)](+) as a novel photoactivatable CO-releasing molecule with well-defined iCORM intermediates - synthesis, spectroscopy, and antibacterial activity. Nagel C; McLean S; Poole RK; Braunschweig H; Kramer T; Schatzschneider U Dalton Trans; 2014 Jul; 43(26):9986-97. PubMed ID: 24855638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]